This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: GenVec

Jeff Taylor writes, " I haven't written in a while. Perhaps a few years ago you recall that I pointed GenVec (GNVC) out to you. I have a little experience here. My take is this licensing deal with Novartis (NVS) for hearing loss is just a bonus. The rocket ship leaves when the interim on the 184th event for the PACT trial is released in about 10 weeks. This will put it in lock step with ASCO. For those of us nibbling at the under-a-dollar prices, the train has left the station."

I found plenty of reasons to be cautious about TNFerade, GenVec's gene therapy drug for pancreatic cancer, after the company released data from the first interim analysis of the phase III study in November 2008. I won't go over the details here because you can go back and read my analysis.

One lesson I learned painfully last year is that long-shot drugs can and do surprise to the upside, so it would be foolish to totally dismiss the possibility of more positive results from the second interim look at the TNFerade "PACT" study, which, as Jeff points out, should be released at the end of March.

Speculative investors are thinking along the same lines, which explains why GenVec shares have almost doubled since the end of December. (The stock closed Thursday at $2.39.)

Regarding Tuesday's licensing pact between GenVec and Novartis for a preclinical (very early stage) hearing loss treatment, and whether or not it has deeper meaning, I'm in agreement with BNET's Trista Morrison, who wrote of the deal:

"I can think of two possible reasons: 1) Novartis didn't want TNFerade, or 2) Novartis did want TNFerade but would rather pay a scant $7 million upfront to test the waters in a preclinical program before committing to Phase III economics ahead of a risky data read-out. Or maybe Novartis just thought the hearing loss program was cool...but heck, you gotta wonder if somebody is eventually going to take the plunge and place a bigger gene therapy bet on TNFerade."

I will add that GenVec executives were talking about the importance of finding a TNFerade partner soon back in 2008. A deal still hasn't happened.

Needless to say, the upcoming second look at the TNFerde data should tell us a lot.

2 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs